T1	p 61 114	bestatin of acute nonlymphocytic leukemia in adults .
T2	p 380 461	remission maintenance chemotherapy for adult acute nonlymphocytic leukemia ( ANLL
T3	p 622 674	. The 101 eligible cases ( bestatin : 48 , control :
T4	p 927 949	the 15-49 yr age group
T5	p 955 971	the 50-65 yr age
T6	p 1151 1167	elderly patients
T7	i 37 55	chemoimmunotherapy
T8	i 61 69	bestatin
T9	i 121 137	immunomodulating
T10	i 146 154	bestatin
T11	i 337 359	bestatin immunotherapy
T12	i 363 374	combination
T13	i 390 414	maintenance chemotherapy
T14	i 552 566	bestatin group
T15	i 572 577	mg/bw
T16	i 587 591	po )
T17	i 608 615	control
T18	i 700 708	bestatin
T19	i 1008 1016	Bestatin
T20	o 731 740	remission
T21	o 803 813	survival .
T22	o 826 851	prolongation of remission
T23	o 1114 1136	survival and remission